Sandbox/AIRSG

Revision as of 19:32, 10 March 2014 by Alejandro Lemor (talk | contribs) (Created page with "__NOTOC__ {{WikiDoc CMG}}; {{AE}} {{AL}} ==Definition== Aortic insufficiency is the ==Causes== ===Life Threatening Causes=== Life-threatening causes include conditions ...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]

Definition

Aortic insufficiency is the

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.

  • [[

Common Causes

  • [[
  • [[
  • [[
  • [[

Management

Shown below is an algorithm summarizing the approach to aortic insufficiency [1][2]


 
 
 
 
Characterize the symptoms:
❑ Most patients are asymptomatic
Dyspnea on exertion
❑ Exertional dizziness
❑ Exertional angina
Syncope
Chest pain
Palpitations
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inquire about past medical history:
❑ Previously healthy
Cardiac disease:
Hypertension
Bicuspid aortic valve
Rheumatic fever
Pulmonary disease
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Examine the patient:

❑ Heart rate
❑ Pulses

Pulsus parvus et tardus

❑ Cardiac palpation

❑ Apical impulse (due to LVH)
Systolic thrill

❑ Cardiac auscultation

❑ Crescendo-decrescendo systolic ejection murmur with ejection click
❑ Best heard at the upper right sternal border
❑ Bilateral radiation to the carotid arteries
❑ Murmur increases with: squatting, expiration
❑ Murmur decreases with valsalva maneuver
❑ Pulmonary auscultation: search for rales (seen when congestive heart failure has developed)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Order imaging studies:
❑ Order an echocardiography, assess:
❑ Valve morphology
❑ Pressure gradient
❑ Aortic valve area
❑ Ejection fraction
❑ LV wall thickness and motility

❑ Order a CXR, look for:

Cardiomegaly
❑ Valve calcification
❑ Dilatation of ascending aorta
❑ Pulmonary congestion

❑ Order a ECG, look for:

LVH
❑ Left atrium enlargement
LBBB
AF (in late disease)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interpret results from echo
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No stenosis (Stage A)
❑ Valve area 2.5-3.5 cm²
❑ No pressure gradient
 
Mild to moderate stenosis (Stage B)
Mild:
❑ Valve area 1.5-2.5 cm²
❑ Pressure gradient ≤ 25 mmHg
Moderate:
❑ Valve area 1.0-1.5 cm²
❑ Pressure gradient 25-40 mmHg
 
 
 
 
 
Severe stenosis
❑ Valve area ≤ 1.0 cm²
❑ Pressure gradient ≥ 40 mmHg
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Normal valve
❑ Bicuspid valve
❑ Sclerotic valve
 
Perform a periodic echocardiogram (Class I; Level of Evidence: B)
❑ Every 3 -5 yrs for mild stenosis
❑ Every 1 - 2 yrs for moderate stenosis
 
 
 
Patient asymptomatic
(Stage C)
 
 
 
 
Patient symptomatic
(Stage D)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control hypertension (Class I; Level of Evidence: B)
 
If patient undergoes another cardiac surgery:
Schedule for AVR (Class IIa; Level of Evidence: C)
 
Normal LVEF
(Stage C1)
 
LVEF < 50%
(Stage C2)
 
High gradient (ΔP ≥ 40 mmHg)
(Stage D1)
 
Low gradient (ΔP ≤ 40 mmHg)
❑ Normal LVEF (Stage D2)
❑ LVEF < 50% (Stage D3)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Perform a periodic echocardiogram every 6 - 12 months (Class I; Level of Evidence: B)
 
 
Schedule for AVR (Class I; Level of Evidence: A)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If aortic velocity ≥ 5 m/s or decrease in exercise tolerance:
Schedule for AVR (Class IIa; Level of Evidence: B)
 
 
 
 
 
 
 
 
 
 
 
 
 



LVH: Left ventricle hypertrophy; CXR: Chest x-ray; ECG: Electrocardiogram; LBBB: Left bundle branch block; AF: Atrial fibrillation; AVR: Aortic valve replacement; VHD: Valve heart disease; TAVR: Transcatheter aortic valve replacement

Choice of intervention

Shown below is an algorithm summarizing the choice of the intervention to aortic stenosis [1]

 
 
 
 
 
 
Patient scheduled for AVR
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
High risk[3]
❑ STS Score[4] > 10
❑ EuroScore[5] > 20
 
 
 
 
 
Low to moderate risk[3]
❑ STS Score[4] < 10
❑ EuroScore[5] < 20
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ A multidisciplinary group of physicians with expertise in VHD,
cardiac imaging, interventional cardiology, cardiac anesthesia, and
cardiac surgery should decide intervention (Surgical AVR or
TAVR) (Class I; Level of Evidence: C)
❑ Schedule for TAVR (Class IIa; Level of Evidence: B)[1] [6]
 
 
 
 
 
❑ Schedule for surgical AVR (Class I; Level of Evidence: A)
 
 
 
 


STS: Society of Thoracic Surgeons

Type of valve and anticoagulation therapy

 
 
 
 
 
 
Age of patient?
Anti-coagulation contraindications?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Patients ≤ 70 years old (Class IIa; Level of Evidence: B)
 
 
 
 
 
❑ Patients with anticoagulant therapy contraindications
(Class I; Level of Evidence: C)
❑ Patients ≥ 70 years old (Class IIa; Level of Evidence: B)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mechanical Prosthesis
 
 
 
 
 
Bioprosthesis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient with risk factors
 
Patient without risk factors
 
AVR
 
TAVR
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Give warfarin to achieve INR of 3.0
❑ Give aspirin 75-100 mg/d
❑ Both long term
 
❑ Give warfarin to achieve INR of 2.5
❑ Give aspirin 75-100 mg/d
❑ Both long term
 
❑ Give warfarin to achieve INR of 2.5 for 3 months
❑ Then give aspirin 75-100 mg/d long term
 
❑ Give clopidrogel 75 mg/d
❑ Give aspirin 75-100 mg/d
❑ Both for 6 months
 


❑ Either a bioprosthetic or mechanical valve is reasonable in patients between 60 and 70 years of age. (Class IIa; Level of Evidence: B).

Do's

❑ Give ACE inhibitors to control hypertension in patients with asymptomatic aortic stenosis. [7]
❑ Exercise testing in asymptomatic patients with AS may be considered to elicit exercise-induced symptoms and abnormal blood pressure responses (Class IIb; Level of Evidence: B).
❑ Dobutamine stress echocardiography is reasonable to evaluate patients with low-flow/low-gradient AS and LV dysfunction (Stage D3) (Class IIa; Level of Evidence: B)
❑ Aortic balloon valvotomy might be reasonable as a bridge to surgery in hemodynamically unstable adult patients with AS who are at high risk for AVR or cannot be performed because of serious comorbid conditions.(Class IIb; Level of Evidence: C).

Don'ts

❑ Do not perform a stress test in a symptomatic patient with stage D aortic stenosis (Class III; Level of Evidence: B).
❑ Do not give statins to prevent hemodynamic progression in patients with mild to moderate calcific aortic valve disease (Class III; Level of Evidence: A).
TAVR is not recommended in patients in whom existing comorbidities would preclude the expected benefit from correction of AS (Class III; Level of Evidence: B)
❑ Do not give vasodilators to patients with severe AS as they may cause severe hypotension.
Endocarditis prophylaxis is not indicated in patients with AR. [8]

References

  1. 1.0 1.1 1.2 "2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary". Retrieved 4 March 2014.
  2. Bonow, R. O.; Carabello, B. A.; Chatterjee, K.; de Leon, A. C.; Faxon, D. P.; Freed, M. D.; Gaasch, W. H.; Lytle, B. W.; Nishimura, R. A.; O'Gara, P. T.; O'Rourke, R. A.; Otto, C. M.; Shah, P. M.; Shanewise, J. S. (2008). "2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". Circulation. 118 (15): e523–e661. doi:10.1161/CIRCULATIONAHA.108.190748. ISSN 0009-7322.
  3. 3.0 3.1 Ben-Dor, I.; Pichard, A. D.; Gonzalez, M. A.; Weissman, G.; Li, Y.; Goldstein, S. A.; Okubagzi, P.; Syed, A. I.; Maluenda, G.; Collins, S. D.; Delhaye, C.; Wakabayashi, K.; Gaglia, M. A.; Torguson, R.; Xue, Z.; Satler, L. F.; Suddath, W. O.; Kent, K. M.; Lindsay, J.; Waksman, R. (2010). "Correlates and Causes of Death in Patients With Severe Symptomatic Aortic Stenosis Who Are Not Eligible to Participate in a Clinical Trial of Transcatheter Aortic Valve Implantation". Circulation. 122 (11_suppl_1): S37–S42. doi:10.1161/CIRCULATIONAHA.109.926873. ISSN 0009-7322.
  4. 4.0 4.1 "Online STS Risk Calculator". Retrieved 7 March 2014.
  5. 5.0 5.1 "http://www.euroscore.org/calc.html". Retrieved 7 March 2014. External link in |title= (help)
  6. Smith, Craig R.; Leon, Martin B.; Mack, Michael J.; Miller, D. Craig; Moses, Jeffrey W.; Svensson, Lars G.; Tuzcu, E. Murat; Webb, John G.; Fontana, Gregory P.; Makkar, Raj R.; Williams, Mathew; Dewey, Todd; Kapadia, Samir; Babaliaros, Vasilis; Thourani, Vinod H.; Corso, Paul; Pichard, Augusto D.; Bavaria, Joseph E.; Herrmann, Howard C.; Akin, Jodi J.; Anderson, William N.; Wang, Duolao; Pocock, Stuart J. (2011). "Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients". New England Journal of Medicine. 364 (23): 2187–2198. doi:10.1056/NEJMoa1103510. ISSN 0028-4793.
  7. Chambers, J. (2005). "The left ventricle in aortic stenosis: evidence for the use of ACE inhibitors". Heart. 92 (3): 420–423. doi:10.1136/hrt.2005.074112. ISSN 1355-6037.
  8. Bonow, RO.; Carabello, BA.; Chatterjee, K.; de Leon, AC.; Faxon, DP.; Freed, MD.; Gaasch, WH.; Lytle, BW.; Nishimura, RA. (2008). "2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". Circulation. 118 (15): e523–661. doi:10.1161/CIRCULATIONAHA.108.190748. PMID 18820172. Unknown parameter |month= ignored (help)


Template:WikiDoc Sources